Quest Diagnostics, one of the nation’s largest clinical laboratory companies, is venturing into mental health screening through a partnership with Catapult Health that offers virtual depression assessments as part of comprehensive preventive care checkups for employer populations. The move signals how mainstream behavioral health has become in workplace wellness programs and reflects growing recognition that mental health fundamentally influences the physical health metrics that employers and health plans try to improve.
The partnership combines Quest’s established presence in employer biometric screening and lab testing with Catapult Health’s preventive primary care platform, creating an integrated offering that addresses both physical and mental health risk factors. For Quest, traditionally focused on measuring cholesterol, blood sugar, and other physical biomarkers, adding mental health screening represents strategic acknowledgment that psychological wellbeing drives many of the chronic disease outcomes employers want to prevent.
The collaboration also illustrates how non-traditional players are entering behavioral health space as the sector’s importance becomes undeniable and integration with physical health becomes operationally feasible through technology platforms enabling virtual screening and follow-up care.
The Strategic Logic Behind Quest’s Mental Health Move
Quest Diagnostics built its employer health business around biometric screening and laboratory testing—measuring employee populations’ height, weight, blood pressure, cholesterol, glucose, and other physical health markers. These screenings help employers identify workers at risk for diabetes, cardiovascular disease, and other chronic conditions that drive healthcare costs.
However, physical biomarkers tell incomplete stories. Depression and anxiety contribute to obesity, hypertension, diabetes, and cardiovascular disease. Stress affects immune function and inflammatory processes. Substance use disorders complicate chronic disease management. Mental health fundamentally influences the physical health outcomes Quest’s employer clients are trying to improve.
Wendi Mader, executive director and commercial leader for Quest Diagnostics, explained the company’s thinking: “Historically, Quest has mostly focused on physical health, doing biometric screenings to monitor things like height, weight and blood pressure. But behavioral health can majorly contribute to many physical health measures, which is why Quest was bullish on preventative mental health screenings.”
This recognition that “behavioral health can majorly contribute to many physical health measures” reflects the broader healthcare industry’s evolution toward integrated care models. The artificial separation between behavioral and physical health has long hindered effective care delivery. Quest’s partnership with Catapult represents pragmatic acknowledgment that addressing mental health is essential to achieving the chronic disease prevention goals employers pursue through workplace wellness programs.
Rather than building mental health capabilities from scratch, Quest partnered with Catapult Health, a provider already offering preventive primary care services including mental health components to employers and health plans nationwide. Mader noted that Catapult’s preventive care checkup offering caught Quest’s attention specifically because it included mental health services.
“As part of that primary preventive care checkup, they had mental health services,” Mader told Behavioral Health Business. “We felt that to be an important component.”
This partnership strategy allows Quest to quickly add mental health screening without developing expertise, clinical workflows, and provider networks that fall outside its core laboratory and biometric screening competencies. For Catapult, partnering with Quest provides access to the lab giant’s substantial employer customer base and established market presence.
How the Integrated Screening Works
The combined Quest-Catapult offering delivers comprehensive preventive care checkups that address multiple health dimensions simultaneously. Each checkup includes personal and family health history review, Quest’s laboratory tests and biometric data, medication adherence assessment, and depression screening using the PHQ-9.
The PHQ-9, or Patient Health Questionnaire-9, is a validated tool for detecting and measuring depression severity. The nine-item questionnaire asks about symptoms like loss of interest in activities, sleep problems, energy levels, and thoughts of self-harm. Scores indicate whether individuals likely have no, mild, moderate, moderately severe, or severe depression.
Using a standardized, validated screening tool like PHQ-9 rather than informal assessment provides several advantages. The tool has established sensitivity and specificity for detecting depression, meaning it reliably identifies people who have the condition while minimizing false positives. Standardization allows comparison across populations and tracking of outcomes over time. And the brief questionnaire format makes screening efficient for large employee populations.
After screening, patients receive personalized action plans addressing identified health risks. These plans can include referrals to employer health and benefits programs, lifestyle modification recommendations, and connections to clinical care for issues requiring professional treatment.
The Critical Follow-Up Care Component
While screening is valuable, its impact depends entirely on what happens next. Identifying that someone has depression means nothing if they don’t receive effective treatment. This is where many workplace wellness programs fail—they screen but don’t ensure follow-through to care.
Mader emphasized that Catapult’s ability to connect screened individuals with follow-up care was a major selling point for Quest. “Post-screening, [patients] are scheduling an appointment with Catapult, and they’re talking virtually with a nurse practitioner,” she explained.
This immediate connection to virtual care addresses the typical gap between screening and treatment. Rather than giving employees positive depression screens and telling them to find a therapist on their own—a process that often fails due to provider shortages, insurance barriers, and simple inertia—the program facilitates direct scheduling with nurse practitioners who can conduct assessments, provide counseling, prescribe medications if appropriate, and coordinate referrals to additional resources.
The virtual delivery model makes follow-up care accessible regardless of employee location or work schedule. Workers can connect with nurse practitioners from home without taking time off work or arranging childcare. This convenience dramatically improves the likelihood of follow-through compared to requiring in-person appointments at external providers.
The integration of screening and follow-up care in a single platform creates accountability that stand-alone screening lacks. Catapult knows which employees screened positive and whether they’ve engaged with follow-up care, allowing proactive outreach to individuals who haven’t scheduled appointments.
What This Signals About Employer Behavioral Health Benefits
Quest’s entry into mental health screening reflects broader trends in how employers approach behavioral health benefits. Several dynamics are driving increased employer investment and innovation in workplace mental health.
COVID-19 intensified employee mental health challenges while making the business case for employer intervention undeniable. Workers experiencing depression, anxiety, and burnout are less productive, take more sick days, and face higher risks of physical health problems that drive medical costs. Employers recognize that supporting mental health isn’t just compassionate—it’s economically rational.
The integration of mental and physical health screening acknowledges that these dimensions of health interact continuously. Employers pursuing chronic disease prevention and healthcare cost management increasingly understand that ignoring mental health undermines physical health goals.
Virtual care delivery has made mental health services more accessible and scalable for employer populations. Pre-pandemic, providing mental health benefits meant directing employees to community therapists who often didn’t accept insurance or had long wait times. Virtual platforms can serve employees across geographies and schedules with less friction.
Preventive approaches are gaining favor over reactive crisis response. Screening entire populations to identify emerging issues before they become severe represents upstream intervention that could reduce downstream costs of acute psychiatric care, substance abuse treatment, and disability claims.
The Quest-Catapult partnership specifically targets prevention—catching depression early when interventions can be less intensive and more effective than waiting until employees are in crisis. This preventive orientation aligns with broader healthcare trends toward early intervention and population health management.
Challenges and Limitations
Despite the strategic logic and apparent benefits, the Quest-Catapult model faces several challenges that will determine its real-world effectiveness.
Screening sensitivity and specificity mean PHQ-9 won’t catch everyone with depression and will sometimes flag people who don’t have clinical depression. No screening tool is perfect. Some employees with depression will slip through with negative screens. Others will screen positive but not actually need clinical intervention. Managing both false negatives and false positives requires clinical judgment beyond what screening algorithms provide.
Follow-up care capacity must match screening volume. If thousands of employees screen positive for depression but Catapult can only schedule hundreds for follow-up appointments, long wait times will undermine the value of rapid screening-to-care pathways. Scaling clinical capacity proportionally to screening volume is operationally challenging.
Nurse practitioner care, while valuable, has limitations. Some employees screening positive will need psychiatrists, intensive therapy, or specialized addiction treatment beyond what nurse practitioners provide. The program must have referral pathways to higher levels of care and not position nurse practitioner consultations as sufficient for everyone.
Privacy and stigma concerns may affect participation. Employees might worry that employer-sponsored mental health screening could jeopardize their jobs if depression is detected. Despite legal protections, fear of discrimination could reduce voluntary participation. Virtual care helps somewhat by allowing private access, but the employer sponsorship still creates concerns.
Outcomes measurement will be critical but challenging. Mader acknowledged it’s too early to assess the program’s impact. But eventually, Quest and employers will want evidence that screening and follow-up actually improve employee mental health, reduce absenteeism, boost productivity, and control healthcare costs. Demonstrating these outcomes requires longitudinal data collection and rigorous evaluation.
The Bigger Picture: Behavioral Health Goes Mainstream
Quest Diagnostics partnering with Catapult Health to offer mental health screening represents more than just one company’s strategic move. It symbolizes behavioral health’s arrival as a mainstream component of workplace wellness and population health management.
When one of the nation’s largest laboratory companies—an organization built around measuring cholesterol and blood glucose—adds depression screening to its employer offerings, it signals that mental health is no longer niche or peripheral. It’s central to health and wellbeing in ways that major healthcare companies now recognize and act upon.
This mainstreaming creates both opportunities and risks. Opportunities include expanded access as large players with substantial resources and reach bring mental health services to populations that might not otherwise access them. The Quest-Catapult program will screen employees who would never seek mental health care independently but will complete assessments as part of routine workplace health checks.
Risks include superficial engagement where screening happens without adequate follow-through, or where mental health becomes another checkbox in wellness programs focused more on optics than outcomes. The effectiveness of these initiatives depends entirely on execution—whether screening leads to actual care, whether care is appropriate and sufficient, and whether outcomes improve.
For behavioral health providers, Quest’s entry creates both competition and partnership opportunities. The company is entering mental health screening through partnership rather than trying to build capabilities independently. Other behavioral health organizations could potentially partner with Quest or similar employers to provide follow-up care, expanding their reach to employer populations.
For employees, the integration of mental health screening into routine workplace health assessments could reduce stigma by normalizing mental health as part of overall health. When depression screening sits alongside cholesterol and blood pressure measurement, it sends messages that mental health is health—not something separate or shameful.
Looking Ahead
Mader indicated that Quest has begun signing employer clients for the Catapult program but that it’s too soon to evaluate impact. The coming months will reveal whether employers find value in integrated physical-behavioral health screening and whether employees engage with both the screenings and follow-up care.
If the program succeeds—demonstrating that integrated screening improves employee health outcomes and employer costs—it could accelerate similar partnerships between traditional healthcare companies and behavioral health providers. Other laboratory companies, biometric screening firms, and wellness vendors might add mental health components to remain competitive.
If the program struggles—with low employee participation, inadequate follow-up care capacity, or failure to demonstrate meaningful outcomes—it would raise questions about whether workplace mental health screening can move beyond pilot programs to scaled implementation.
For now, Quest Diagnostics’ move into mental health screening illustrates how thoroughly behavioral health has penetrated mainstream healthcare thinking. When the companies measuring our cholesterol also screen our depression, mental health has clearly arrived as a core health dimension that can no longer be separated, siloed, or ignored.
Whether that integration translates to better care and outcomes for the employees being screened remains to be demonstrated. But the strategic shift itself—lab giants recognizing that mental health matters to physical health and acting on that recognition—represents progress toward the integrated care models that healthcare has discussed for decades but struggled to operationalize.
